The Octus MCP Connector Puts the Most Expansive, Accurate and Verified Credit Intelligence and Data Directly Inside Claude, ChatGPT and Other LLMs July 14, 2026 Octus subscribers can now route credit intelligence, data and deal documents directly into the AI tools they use every day, with source attribution on every output
Rehlko Announces €12 Million Expansion of Power Control & Distribution Manufacturing Facility in Cholet, France July 14, 2026 Strategic investment scales Cholet production facility by over 50%, reducing lead time by 30% to meet growing digital infrastructure demand
Dompé Doses First Patient in Phase 3 Study of Cenegermin-bkbj in NAION July 14, 2026 Non-arteritic anterior ischemic optic neuropathy (NAION) is a loss of blood flow to the optic nerve which causes spontaneous and rapid vision loss, for which there are currently no FDA-approved treatments. Given the substantial unmet need for effective treatments in NAION, in October 2025, Dompé was awarded a Commissioner’s National Priority Review Voucher (CNPV) by the US FDA to accelerate a potential Biologics License Application for intranasal nerve growth factor (NGF) in NAION.
ACE Welcomes Telekom Srbija Group as Newest Member, Expanding Anti-Piracy Fight in Southeast Europe July 14, 2026 Top Telecommunications and Media Group Joins Global Coalition Protecting Creative Content and Strengthening Lawful Digital Markets
STARTEEPO Increases Xerox Position to 8.8 Million Shares, Becomes Second-Largest Common Shareholder July 14, 2026 STARTEEPO Invest (“STARTEEPO”), a Prague-based alternative investment fund focused on high-conviction public equity investments, today announced that it has increased its beneficial ownership position in Xerox Holdings Corporation (“Xerox” or the “Company”) to 8.8 million common shares, together with options on an additional 140,000 shares, as disclosed in an amended Schedule 13D filing with the [...]
Real Chemistry Launches Real Chemistry ANATOMI, an AI Ecosystem Purpose-Built for Healthcare Commercialization July 14, 2026 The unique combination of technology marks 25 years of industry innovation and expertise, and signals company’s next phase of business growth and client value
Insulet Partners with Calm to Bring Mindfulness and Well-Being Tools to the Diabetes Community, Featuring a New Sleep Story Narrated by Lila Moss July 14, 2026 The partnership introduces The Mind in Range Collection, a set of tailored mindfulness resources available at no cost to the diabetes community, including a meditation series, a breathing exercise, and a new Calm Sleep Story narrated by Omnipod® user and fashion model Lila Moss, designed to help listeners unwind and feel supported With 359 million people worldwide living with an anxiety disorder1, and people with diabetes being 20% more likely to develop anxiety2, this initiative reinforces Insulet’s commitment to whole-person care and positions mental health as essential to diabetes management The integrated content collaboration is the first-of-its-kind between Calm and a MedTech company, built on Insulet's global research showing the essential role emotional well-being plays in diabetes management
Xsolla Connect Returns to Brighton July 13, 2026 Connecting The UK Game Development Community For Networking And Insights During Develop:Brighton
Cloudflare Introduces Precursor; One-Click Behavioral Defense Against Modern Bots July 13, 2026 Built on one of the world’s largest networks, Precursor is the only defense of its kind to replace disruptive checkpoints to stop evasive bots without slowing down users
Tenpoint Therapeutics Announces United Kingdom Submission of Marketing Authorization Application to the Medicines and Healthcare Products Regulatory Agency (MHRA) for the Treatment of Blurry Close-Up Vision (Presbyopia) in Adults July 13, 2026 The product, branded YUVEZZI™, received approval from the U.S. Food and Drug Administration (FDA) in January 2026 as the first and only dual-agent (combination) eye drop approved for the treatment of presbyopia in adults The United Kingdom submission is an important milestone for Tenpoint Therapeutics’ continued global expansion strategy